April 1, 2019 - FDA Approves Pembrolizumab For First-line Treatment Of Lung Cancer

The FDA granted approval to pembrolizumab (Keytruda, Merck), an anti-PD-1 checkpoint immunotherapy, for first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) that is PD-L1-positive and is not amenable to surgery or chemo-radiation treatment.

Search for latest news on pembrolizumab

Meet Dr. Julie Brahmer, Scientific Advisory Board member at LCFA and leader in immunotherapy research.